Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT06890338 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06890338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06890338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
November 21, 2025
Completion date
February 28, 2030
Enrollment
140 (estimated)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, fallopian tube cancer, neoadjuvant, primary peritoneal cancer